ClinicalTrials.Veeva

Menu

Imaging Synapses With [11C] UCB-J in the Human Brain

D

Davidzon, Guido, M.D.

Status and phase

Enrolling
Phase 1

Conditions

Schizophrenia

Treatments

Drug: [11C]UCB-J radiotracer
Device: PET-MR

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer [11C]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. This imaging method allows for the quantification of synaptic density in the living human brain and has the unprecedented ability to directly examine the synaptic pathology underlying neuropsychiatric disease. The neural synaptic pruning hypothesis posits that a key pathogenic process of schizophrenia is the over-exuberant elimination of neural synapses during development. The confirmation of reduced synaptic density in schizophrenia as evidenced by [11C]UCB-J has the potential to lead to a number of ground-breaking clinical innovations, such as laboratory-based diagnostics and prognostics, and novel, disease-modifying treatments.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • 18 - 65 years in age

  • For SZ participants:

    • On a stable medication regimen for at least two weeks prior to testing
    • A clinical diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder
    • Able to complete a PET-MR scan without the use of sedation

Exclusion criteria

  • Active substance use within three months of testing

  • IQ < 70

  • Major medical neurological illness or significant head trauma

  • Pregnancy or breastfeeding

  • Contraindication to MR scanning, including magnetic-resonance incompatible metal or hardware including pacemakers, cochlear implants, and bullets near a critical organ

  • Weight > 350 lbs or a large body habitus that MR scanner cannot accommodate

  • History of or current claustrophobia

  • Inability to comply with basic study requirements such as following directions and punctuality

  • For HC participants:

    • Presence of a first degree relative with a psychotic disorder
    • Lifetime diagnosis of major psychiatric illness
  • For SZ participants:

    • Unstable psychiatric symptoms at the time of testing, e.g. acute suicidality, prominent psychosis, or behavioral dyscontrol

Trial design

Primary purpose

Other

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

60 participants in 2 patient groups

Healthy Control (HC) Participants
Experimental group
Description:
Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the \[11C\]UCB-J radiotracer
Treatment:
Device: PET-MR
Drug: [11C]UCB-J radiotracer
Schizophrenia (SZ) Participants
Experimental group
Description:
Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the \[11C\]UCB-J radiotracer
Treatment:
Device: PET-MR
Drug: [11C]UCB-J radiotracer

Trial contacts and locations

2

Loading...

Central trial contact

Study Coordinator; Study Coordinator 2

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems